Clinical trial
A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza
NCT00440362 · AlphaVax, Inc., Industry · Completed
Key facts
| NCT number | NCT00440362 |
|---|---|
| Title | A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza |
| Official title | A Single-Site, Phase 1/2, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Healthy Volunteers |
| Lead sponsor | AlphaVax, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | AVX502, Placebo |
| Enrollment | 216 |
| Start date | Apr 1, 2007 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Feb 27, 2007 |
| Last update posted | Nov 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: